PLYX
Polaryx Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$2.00
+0.50%Institutional positioning
13F filings over the trailing two quarters
New 14Increased 0Reduced 0Sold out 14
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,658,388 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | New Position | 170,673 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | New Position | 127,525 | May 15, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 104,556 | May 8, 2026 |
| STATE STREET CORP | New Position | 58,104 | May 15, 2026 |
| BLACKROCK, INC. | New Position | 41,012 | May 13, 2026 |
| NORTHERN TRUST CORP | New Position | 27,987 | May 14, 2026 |
| BANK OF AMERICA CORP /DE/ | New Position | 25,881 | May 18, 2026 |
| GOLDMAN SACHS GROUP INC | New Position | 13,483 | May 15, 2026 |
| UBS GROUP AG | New Position | 13,479 | May 5, 2026 |
| SQUAREPOINT OPS LLC | New Position | 12,406 | May 15, 2026 |
| VANGUARD GLOBAL ADVISERS, LLC | New Position | 6,318 | May 8, 2026 |
| MORGAN STANLEY | New Position | 5,543 | May 15, 2026 |
| TOWER RESEARCH CAPITAL LLC (TRC) | New Position | 1,781 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Sold Out | 0 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings